trending Market Intelligence /marketintelligence/en/news-insights/trending/mw7A5Yuv68Etj3nA7iOfOA2 content esgSubNav
In This List

Biotricity's remote heart disease monitoring device secures US FDA clearance

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Biotricity's remote heart disease monitoring device secures US FDA clearance

The U.S. Food and Drug Administration granted 510(k) clearance to Biotricity Inc.'s Bioflux device.

Bioflux consists of a proprietary mobile electrocardiography or ECG monitoring device and an ECG viewer software package that enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease.